@article{JTD9104,
author = {Hyung-Joo Oh and Ha-Young Park and Ki-Hyun Kim and Cheol-Kyu Park and Hong-Joon Shin and Jung-Hwan Lim and Yong-Soo Kwon and In-Jae Oh and Yu-Il Kim and Sung-Chul Lim and Young-Chul Kim and Soo-Hyun Kim and Myung-Geun Shin},
title = {Progastrin-releasing peptide as a diagnostic and therapeutic biomarker of small cell lung cancer},
journal = {Journal of Thoracic Disease},
volume = {8},
number = {9},
year = {2016},
keywords = {},
abstract = {Background: Progastrin-releasing peptide (proGRP) is a recently identified biomarker of small cell lung cancer (SCLC). We evaluated the usefulness of plasma proGRP level as a tumor marker for diagnosis and treatment monitoring in patients with SCLC.
Methods: Plasma samples were collected prospectively from 452 [212 non-small cell lung cancer (NSCLC), 105 SCLC, and 135 other diseases] patients who visited the hospital for tissue diagnosis. Plasma proGRP levels were measured using a two-step automated immunoassay.
Results: The median proGRP level was significantly higher in patients with SCLC (892.7 pg/mL) than those with NSCLC (32.6 pg/mL, P},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/9104}
}